Patent · US Active

Dual delivery system for heterologous antigens

US9644212B2 · kind B2 · utility

10Cited by
69References
10Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMar 11, 2014
Grant dateMay 9, 2017
Priority date
Expiry dateJul 26, 2034

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K2039/6006
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Provided herein are recombinant Listeria strains expressing a tumor-specific antigenic polypeptide and, optionally, an angiogenic polypeptide wherein a nucleic acid molecule encoding at least one of the polypeptides is operably integrated into the Listeria genome in an open reading frame with a nucleic acid sequence encoding a PEST-containing polypeptide, methods of preparing same, and methods of inducing an immune response, and treating, inhibiting, or suppressing cancer or tumors comprising administering same.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.